<p>JonesTrading 分析師 Justin Walsh 重申了對 PRAX 股票的看漲態度，今天給予了買入評級。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
<p>Justin Walsh 給予買入評級是基於與 Praxis Precision Medicines 癲癇產品組合相關的多種因素。最近在 2025 年美國癲癇學會年會上發佈的臨牀更新突出了顯著的進展，特別是關於 relutrigine 的 EMBOLD 試驗，該試驗因其療效而提前停止。試驗結果顯示，安慰劑調整後的癲癇發作減少顯著，且患者無運動性癲癇發作的天數增加，臨牀醫生和護理人員對患者改善的反饋積極。</p>
<p>此外，vormatrigine 的 RADIANT 試驗結果也令人鼓舞，表明其作為最佳抗癲癇藥物的潛力。vormatrigine 顯示出顯著的癲癇發作減少，且相當一部分患者在無需調整劑量的情況下實現了發作自由。該藥物還顯示出良好的相互作用特徵，適合多藥物方案。憑藉這些令人鼓舞的結果和即將發佈的關鍵研究數據，Walsh 認為 Praxis Precision Medicines 的資產有強大的潛力惠及廣泛的患者羣體，從而證明了買入評級的合理性。</p>
<p>在今天發佈的另一份報告中，Guggenheim 也重申了對該股票的買入評級，目標價為 760.00 美元。</p>

PRAX

<p>JonesTrading 分析師 Justin Walsh 重申了對 Praxis Precision Medicines 的買入評級，原因是其癲癇藥物組合的進展令人鼓舞。relutrigine 的 EMBOLD 試驗顯示出顯著的療效，導致提前終止，而 vormatrigine 的 RADIANT 試驗則表明其作為一種頂級抗癲癇藥物的潛力。Guggenheim 也維持了買入評級，目標價為 760 美元，強調了 Praxis 的資產對患者的強大潛力</p>

<p>JonesTrading analyst Justin Walsh has reiterated their bullish stance on PRAX stock, giving a Buy rating today.</p>
<div class="lb-trans"><p>JonesTrading 分析師 Justin Walsh 重申了對 PRAX 股票的看漲態度，今天給予了買入評級。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，讓您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
</div><p>Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Praxis Precision Medicines’ epilepsy portfolio. The recent clinical update at the 2025 American Epilepsy Society Annual Meeting highlighted significant advancements, particularly with the EMBOLD trial of relutrigine, which was stopped early due to its efficacy. The trial results showed a notable placebo-adjusted seizure reduction and an increase in motor seizure-free days, with positive feedback from clinicians and caregivers regarding patient improvement.</p>
<div class="lb-trans"><p>Justin Walsh 給予買入評級是基於與 Praxis Precision Medicines 癲癇產品組合相關的多種因素。最近在 2025 年美國癲癇學會年會上發佈的臨牀更新突出了顯著的進展，特別是關於 relutrigine 的 EMBOLD 試驗，該試驗因其療效而提前停止。試驗結果顯示，安慰劑調整後的癲癇發作減少顯著，且患者無運動性癲癇發作的天數增加，臨牀醫生和護理人員對患者改善的反饋積極。</p>
</div><p>Additionally, the RADIANT trial results for vormatrigine were promising, indicating its potential as a best-in-disease antiseizure medication. Vormatrigine demonstrated a significant reduction in seizures, with a substantial portion of patients achieving seizure freedom without the need for titration. The drug also showed a favorable interaction profile, making it suitable for multi-drug regimens. With these encouraging outcomes and upcoming pivotal study data, Walsh sees strong potential for Praxis Precision Medicines’ assets to benefit a wide range of patients, justifying the Buy rating.</p>
<div class="lb-trans"><p>此外，vormatrigine 的 RADIANT 試驗結果也令人鼓舞，表明其作為最佳抗癲癇藥物的潛力。vormatrigine 顯示出顯著的癲癇發作減少，且相當一部分患者在無需調整劑量的情況下實現了發作自由。該藥物還顯示出良好的相互作用特徵，適合多藥物方案。憑藉這些令人鼓舞的結果和即將發佈的關鍵研究數據，Walsh 認為 Praxis Precision Medicines 的資產有強大的潛力惠及廣泛的患者羣體，從而證明了買入評級的合理性。</p>
</div><p>In another report released today, Guggenheim also reiterated a Buy rating on the stock with a $760.00 price target.</p>
<div class="lb-trans"><p>在今天發佈的另一份報告中，Guggenheim 也重申了對該股票的買入評級，目標價為 760.00 美元。</p>
</div>

Praxis Precision Medicines：有前景的癲癇產品組合的進展證明了買入評級的合理性